Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Datasets
Search by expertise, name or affiliation
Current and future pharmaceutical therapy for rheumatoid arthritis
Eric M. Ruderman
*
*
Corresponding author for this work
Medicine, Rheumatology Division
Research output
:
Contribution to journal
›
Review article
›
peer-review
18
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Current and future pharmaceutical therapy for rheumatoid arthritis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Rheumatoid Arthritis
100%
Diseases
83%
Patient
66%
Combination Therapy
50%
Drug Therapy
33%
Methotrexate
33%
Disease-Modifying Antirheumatic Drug
33%
Tumor Necrosis Factor
33%
Prevalence
16%
Disease Exacerbation
16%
Toxicity
16%
Biological Therapy
16%
Chemotherapeutic Agent
16%
Symptom
16%
Drug
16%
Biological Response Modifier
16%
Therapeutic Procedure
16%
INIS
diseases
100%
arthritis
100%
therapy
83%
pharmaceuticals
33%
patients
33%
inflammation
33%
damage
33%
methotrexate
33%
data
16%
drugs
16%
clinical trials
16%
assessments
16%
populations
16%
reviews
16%
toxicity
16%
symptoms
16%
Nursing and Health Professions
Rheumatoid Arthritis
100%
Diseases
83%
Drug Therapy
50%
Combination Therapy
50%
Methotrexate
33%
Health Care Quality
16%
Prevalence
16%
Clinical Assessment
16%
Drug
16%
Toxicity
16%
Disease Exacerbation
16%
Biological Response Modifier
16%
Biological Therapy
16%
Symptom
16%
Pharmacology, Toxicology and Pharmaceutical Science
Rheumatoid Arthritis
100%
Diseases
83%
Clinical Trial
50%
Methotrexate
33%
Antagonist
33%
Anti-Inflammatory Drug
33%
Toxicity
16%
Disease Exacerbation
16%
Prevalence
16%
Biological Response Modifier
16%
Drug
16%
Symptom
16%
Biochemistry, Genetics and Molecular Biology
Methotrexate
33%
Prevalence
16%